DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was ...

Key Insights DexCom's estimated fair value is US$116 based on 2 Stage Free Cash Flow to Equity DexCom is estimated ...

The stock's fall snapped a two-day winning streak.

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Dexcom (Nasdaq: DXCM) today announced a significant internal promotion for a longtime member of its leadership team.

Internationally, Dexcom has seen pockets of strength in key markets, such as Japan and France, where recent type 2 diabetes coverage expansions have driven growth. New Product Launch: Dexcom plans to ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...

URA has entered the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s CGM Stelo.

Both healthcare stocks have impeccable dividend track records and bright futures still ahead. Broader equities have been volatile this year, but that's par for the course. The fact that the stock ...